Literature DB >> 25642873

Outcomes in traumatic brain injury for patients presenting on antiplatelet therapy.

John David Cull1, Lauren M Sakai, Imran Sabir, Brent Johnson, Andrew Tully, Kimberly Nagy, Andrew Dennis, Frederic L Starr, Kimberly Joseph, Dorion Wiley, Henry R Moore, Uretz J Oliphant, Faran Bokhari.   

Abstract

An increasing number of patients are presenting to trauma units with head injuries on antiplatelet therapy (APT). The influence of APT on these patients is poorly defined. This study examines the outcomes of patients on APT presenting to the hospital with blunt head trauma (BHT). Registries of two Level I trauma centers were reviewed for patients older than 40 years of age from January 2008 to December 2011 with BHT. Patients on APT were compared with control subjects. Primary outcome measures were in-hospital mortality, intracranial hemorrhage (ICH), and need for neurosurgical intervention (NI). Hospital length of stay (LOS) was a secondary outcome measure. Multivariate analysis was used and adjusted models included antiplatelet status, age, Injury Severity Score (ISS), and Glasgow coma scale (GCS). Patients meeting inclusion criteria and having complete data (n = 1547) were included in the analysis; 422 (27%) patients were taking APT. Rates of ICH, NI, and in-hospital mortality of patients with BHT in our study were 45.4, 3.1, and 5.8 per cent, respectively. Controlling for age, ISS, and GCS, there was no significant difference in ICH (odds ratio [OR], 0.84; 95% confidence interval [CI], 0.61 to 1.16), NI (OR, 1.26; 95% CI, 0.60 to 2.67), or mortality (OR, 1.79; 95% CI, 0.89 to 3.59) associated with APT. Subgroup analysis revealed that patients with ISS 20 or greater on APT had increased in-hospital mortality (OR, 2.34; 95% CI, 1.03 to 5.31). LOS greater than 14 days was more likely in the APT group than those in the non-APT group (OR, 1.85; 95% CI, 1.09 to 3.12). The effects of antiplatelet therapy in patients with BHT aged 40 years and older showed no difference in ICH, NI, and in-hospital mortality.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25642873

Source DB:  PubMed          Journal:  Am Surg        ISSN: 0003-1348            Impact factor:   0.688


  5 in total

1.  The Effect of Preoperative Antiplatelet Therapy on Hemorrhagic Complications after Decompressive Craniectomy in Patients with Traumatic Brain Injury.

Authors:  Hokyun Han; Eun Jung Koh; Hyunho Choi; Byong-Cheol Kim; Seung Yeob Yang; Keun-Tae Cho
Journal:  Korean J Neurotrauma       Date:  2016-10-31

Review 2.  Safety of Antithrombotic Agents in Elderly Patients with Acute Coronary Syndromes.

Authors:  Bianca Rocca; Steen Husted
Journal:  Drugs Aging       Date:  2016-04       Impact factor: 3.923

3.  Mortality among head trauma patients taking preinjury antithrombotic agents: a retrospective cohort analysis from a Level 1 trauma centre.

Authors:  Sigrid Narum; Odd Brørs; Olav Stokland; Marianne K Kringen
Journal:  BMC Emerg Med       Date:  2016-08-02

4.  Assessment of Platelet Function in Traumatic Brain Injury-A Retrospective Observational Study in the Neuro-Critical Care Setting.

Authors:  Caroline Lindblad; Eric Peter Thelin; Michael Nekludov; Arvid Frostell; David W Nelson; Mikael Svensson; Bo-Michael Bellander
Journal:  Front Neurol       Date:  2018-01-26       Impact factor: 4.003

5.  The Impact of Preinjury Use of Antiplatelet Drugs on Outcomes of Traumatic Brain Injury: A Systematic Review and Meta-Analysis.

Authors:  Li Cheng; Gaoliang Cui; Rong Yang
Journal:  Front Neurol       Date:  2022-02-07       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.